Hikma Pharmaceuticals Plc Director/PDMR Shareholding (6687V)
April 19 2016 - 7:57AM
UK Regulatory
TIDMHIK
RNS Number : 6687V
Hikma Pharmaceuticals Plc
19 April 2016
Annex DTR3
Notification of Transactions of Directors/Persons Discharging
Managerial Responsibility and Connected Persons
All relevant boxes should be completed in block capital
letters
State whether the
notification relates
to (i) a transaction
notified in accordance
with DTR 3.1.2 R,
(ii) a disclosure
made in accordance
with LR 9.8.6R(1)
or (iii) a disclosure
made in accordance
with section 793 of
Name of the Issuer: the Companies Act
Hikma Pharmaceuticals (2006):
1. PLC 2. DTR 3.1.2 R
---- --------------------------------------- ---- ---------------------------
State whether notification
relates to a person
connected with a person
discharging managerial
responsibilities/
Name of person discharging director named in
managerial responsibilities/director: 3 and identify the
Said Darwazah, Mazen connected person:
3. Darwazah and Ali Al-Husry 4. Yes: Darhold Limited
---- --------------------------------------- ---- ---------------------------
Indicate whether the
notification is in
respect of a holding
of the person referred Description of shares
to in 3 or 4 above (including class),
or in respect of a debentures or derivatives
non-beneficial interest: or financial instruments
Beneficial interest relating to shares:
5. Darhold Limited 6. Ordinary Shares
---- --------------------------------------- ---- ---------------------------
Name of registered
shareholders(s) and, State the nature of
if more than one, the transaction:
the number of shares Release of a pledge
held by each of them: of 1,838,028 Ordinary
7. Citibank N.A. 8. Shares
---- --------------------------------------- ---- ---------------------------
Percentage of issued
class acquired (treasury
Number of shares, shares of that class
debentures or financial should not be taken
instruments relating into account when
to shares acquired: calculating percentage):
9. None 10. N/A
---- --------------------------------------- ---- ---------------------------
Percentage of issued
class disposed (treasury
Number of shares, shares of that class
debentures or financial should not be taken
instruments relating into account when
to shares disposed: calculating percentage):
11. None 12. N/A
---- --------------------------------------- ---- ---------------------------
Price per share or Date and place of
value of transaction: transaction:
13. N/A 14. London, 19 April 2016
---- --------------------------------------- ---- ---------------------------
Total holding following
notification and total
percentage holding
following notification
(any treasury shares
should not be taken
into account when
calculating percentage): Date issuer informed
58,053,028 - 24.25 of transaction:
15. per cent. 16. 19 April 2016
---- --------------------------------------- ---- ---------------------------
If a person discharging managerial responsibilities
has been granted options by the issuer complete
the following boxes
-----------------------------------------------------------------------
Period during which
17. Date of grant 18. or date on which exercisable
---- --------------------------- ---- ------------------------------
Total amount paid Description of shares
(if any) for grant or debentures involved
19. of the option 20. (class and number)
---- --------------------------- ---- ------------------------------
Exercise price (if
fixed at time of
grant) or indication Total number of shares
that price is to or debentures over
be fixed at the which options held
21. time of exercise 22. following notification
---- --------------------------- ---- ------------------------------
Name of contact and
telephone number for
23. Any additional information 24. queries
---- --------------------------- ---- ------------------------------
Name of authorised official or issuer responsible
for making notification
Peter Speirs, Company Secretary, Hikma Pharmaceuticals
PLC
Date of notification: 19 April 2016
-------------------------------------------------------
Notes:
This form is intended for use by an issuer to make a RIS
notification required by DTR 3.1.4
(1) An issuer making a notification in respect of a transaction
relating to the shares or debentures of the issuer should complete
boxes 1 to 16, 23 and 24.
(2) An issuer making a notification in respect of a derivative
relating the shares of the issuer should complete boxes 1 to 4, 6,
8, 13, 14, 16, 23 and 24.
(3) An issuer making a notification in respect of options
granted to a director/person discharging managerial
responsibilities should complete boxes 1 to 3 and 17 to 24.
(4) An issuer making a notification in respect of a financial
instrument relating to the shares of the issuer (other than a
debenture) should complete boxes 1 to 4, 6, 8, 9, 11, 13, 14, 16,
23 and 24.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHBBGDSLUBBGLC
(END) Dow Jones Newswires
April 19, 2016 07:57 ET (11:57 GMT)
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024
